U.S. Markets closed

Verinata Health announces agreement with Teva to commercialize verifi test

Illumina (ILMN) announced that Teva (TEVA) signed an exclusive agreement with Verinata Health, an Illumina company, for the commercialization of the verifi non-invasive prenatal test1 in Israel. The MOR Institute for Medical Data, through its relationship with Teva, will provide the verifi prenatal test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality. Under the terms of the five-year agreement, Teva Pharmaceuticals will be the exclusive distributor of the verifi prenatal test in Israel. All tests will be run in Verinata Health’s CLIA-certified laboratory in California. Clalit Health Services will provide reimbursement for the verifi® prenatal test through supplemental insurance.